Please provide your email address to receive an email when new articles are posted on . John O. Mascarenhas, MD, spoke with Healio about a presentation given during the morning session at 14th ...

This group of cancers remains a challenge to diagnose, can be rapidly progressive, and requires complex treatment and follow-up care, research suggests. Despite recent advancements in treatments for ...

There are promising drugs for myeloproliferative neoplasms coming down the pipeline. It is an exciting time for the treatment of myeloproliferative neoplasms (MPNs), as new treatments continue to ...

Please provide your email address to receive an email when new articles are posted on . In this video, John O. Mascarenhas, MD, provided an overview of his presentation at 14th International Congress ...

JAKis significantly reduce thromboembolic event risk in MPN patients, especially with Jakafi in polycythemia vera and myelofibrosis. A meta-analysis of 23 studies showed a 48% reduction in ...

The chronic myeloproliferative neoplasms (MPNs) include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). The most frequent clinical complications of ET and PV ...

Myeloproliferative neoplasms have varied progression rates, and a complex genetic landscape may contribute to heterogeneity in the outcomes of patients with these diseases. Myeloproliferative ...

Atavistik Bio to present the discovery and characterization of novel allosteric JAK2 V617F selective inhibitors that suppress mutant-dependent signaling and proliferation while sparing wild-type ...

For patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced risk for developing hematologic cancers compared with insulin and ...

Thromboses can occur before and after a diagnosis of MPN, leading to high rates of morbidity and mortality. In a recent study, patients with both AA and MPN experienced more thromboses and had much ...